| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,707,595 ) |
| | 2025 | 2025 | LOHOCLA RESEARCH CORP | 106 N MAIN ST | GALENA | IL | 61036 | JO DAVIESS | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 002 | 8 | NIH | 7/28/2025 | $1,707,595 |
| | 2025 | 2024 | LOHOCLA RESEARCH CORP | 106 N MAIN ST | GALENA | IL | 61036 | JO DAVIESS | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 001 | 7 | NIH | 7/23/2025 | $0 |
| | 2025 | 2023 | LOHOCLA RESEARCH CORP | 106 N MAIN ST | GALENA | IL | 61036 | JO DAVIESS | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 5 | NIH | 5/16/2025 | $0 |
| | 2025 | 2022 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 6 | NIH | 1/30/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,850,372 ) |
| | 2024 | 2024 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 001 | 5 | NIH | 3/15/2024 | $139,986 |
| | 2024 | 2024 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 002 | 7 | NIH | 6/24/2024 | $1,710,386 |
| | 2024 | 2023 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 002 | 5 | NIH | 4/3/2024 | $0 |
| | 2024 | 2023 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 5 | NIH | 3/8/2024 | $0 |
| | 2024 | 2022 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 001 | 6 | NIH | 6/24/2024 | $0 |
| | 2024 | 2022 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 6 | NIH | 3/19/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,925,647 ) |
| | 2023 | 2023 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 001 | 5 | NIH | 6/22/2023 | $1,925,647 |
| | 2023 | 2021 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 3 | NIH | 6/1/2023 | -$17,990 |
| | 2023 | 2020 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 2 | NIH | 11/23/2022 | $17,990 |
|
| Issue Date FY: 2022 ( Subtotal = $4,994,317 ) |
| | 2022 | 2022 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 001 | 4 | NIH | 6/24/2022 | $3,283,785 |
| | 2022 | 2022 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | R44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 6 | NIH | 8/25/2022 | $1,710,532 |
| | 2022 | 2021 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 3 | NIH | 6/17/2022 | $17,990 |
| | 2022 | 2020 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 2 | NIH | 6/17/2022 | -$17,990 |
| | 2022 | 2019 | LOHOCLA RESEARCH CORPORATION | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 5 | NIH | 5/27/2022 | $0 |
| | 2022 | 2019 | LOHOCLA RESEARCH CORP | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 001 | 5 | NIH | 6/15/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $4,098,238 ) |
| | 2021 | 2021 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UH3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 3 | NIH | 7/12/2021 | $3,973,837 |
| | 2021 | 2021 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 5 | NIH | 3/5/2021 | $124,401 |
| | 2021 | 2020 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 2 | NIH | 2/2/2021 | $0 |
| | 2021 | 2019 | LOHOCLA RESEARCH CORPORATION | 29 SALEM LN | EVANSTON | IL | 60203-1217 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 001 | 5 | NIH | 8/31/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $3,483,125 ) |
| | 2020 | 2020 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 001 | 2 | NIH | 9/9/2020 | $3,270,473 |
| | 2020 | 2020 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 001 | 2 | NIH | 9/9/2020 | -$3,270,473 |
| | 2020 | 2020 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 2 | NIH | 2/24/2020 | $3,270,473 |
| | 2020 | 2020 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 5 | NIH | 8/26/2020 | $212,652 |
|
| Issue Date FY: 2019 ( Subtotal = $4,801,138 ) |
| | 2019 | 2019 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 003 | 4 | NIH | 2/28/2019 | $918,712 |
| | 2019 | 2019 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 000 | 1 | NIH | 3/8/2019 | $2,382,426 |
| | 2019 | 2019 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | UG3DA047680 | A novel therapeutic to ameliorate chronic pain and reduce opiate use | 001 | 1 | NIH | 4/29/2019 | $0 |
| | 2019 | 2019 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 004 | 5 | NIH | 8/23/2019 | $1,500,000 |
| | 2019 | 2017 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 002 | 3 | NIH | 12/20/2018 | $35,771 |
| | 2019 | 2016 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 2 | NIH | 10/24/2018 | $0 |
| | 2019 | 2016 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 001 | 2 | NIH | 12/20/2018 | -$35,771 |
|
| Issue Date FY: 2018 ( Subtotal = $1,500,000 ) |
| | 2018 | 2018 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 4 | NIH | 8/21/2018 | $1,500,000 |
|
| Issue Date FY: 2017 ( Subtotal = $1,500,000 ) |
| | 2017 | 2017 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 001 | 3 | NIH | 9/12/2017 | $1,500,000 |
| | 2017 | 2016 | LOHOCLA RESEARCH CORPORATION | 505 CHICAGO AVE | EVANSTON | IL | 60202-2916 | COOK | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 2 | NIH | 9/12/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $985,777 ) |
| | 2016 | 2016 | LOHOCLA RESEARCH CORPORATION | 1200 Olive St | Denver | CO | 80220-2939 | DENVER | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 2 | NIH | 8/12/2016 | $985,777 |
|
| Issue Date FY: 2015 ( Subtotal = $1,000,000 ) |
| | 2015 | 2015 | LOHOCLA RESEARCH CORPORATION | 1200 Olive St | Denver | CO | 80220-2939 | DENVER | USA | U44AA024905 | Nezavist a Novel Molecule for Treatment of Alcohol Use Disorder | 000 | 1 | NIH | 9/23/2015 | $1,000,000 |
|
|
